Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system disorders [1][6] - The company will present new data at the American Epilepsy Society Annual Meeting regarding the RNS® System and its correlation with seizure frequency reduction [2][3] Company Overview - Rapport Therapeutics specializes in precision medicines targeting CNS disorders, leveraging its RAP technology platform to create differentiated product candidates [6] - The lead product candidate, RAP-219, is a negative allosteric modulator designed to selectively target TARPγ8, which is expressed in specific brain regions [5][6] Clinical Trials and Research - A Phase 2a proof-of-concept trial for RAP-219 is underway, focusing on its efficacy as an anti-seizure treatment for drug-resistant focal epilepsy [2] - The trial aims to demonstrate a reduction in long episode frequency and clinically meaningful reduction in patient-reported seizures [2] Upcoming Presentations - Rapport will showcase multiple posters at the AES Annual Meeting, including studies on the antiseizure effects of TARPγ8 modulators and the pharmacokinetics of RAP-219 [3] - The presentations will cover the evolution of RAP-219 and its potential as a treatment for various CNS disorders [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-42121 Rapport Therapeutics, Inc. (Exact Name of Registrant as Specified in its Ch ...

Financial Performance - The company reported a net loss of $17.5 million for Q3 2024, compared to a net loss of $8.7 million in the same period last year, reflecting a 100% increase in losses [15]. - Net loss for the three months ended September 30, 2024, was $17,537,000, compared to a net loss of $8,709,000 in the prior year, representing a 101% increase in losses [25]. - The company reported a net cash increase of $(70,850,000) for the three months ended September 30, 2024, compared to an increase of $79,884,000 in the same period of 2023 [26]. Expenses - Research and development expenses rose to $15.5 million in Q3 2024, up from $7.6 million in the prior year, indicating a 104% increase driven by clinical development costs [15]. - General and administrative expenses increased to $6.1 million in Q3 2024, compared to $2.0 million in the prior year, representing a 205% increase due to business growth and public company requirements [15]. - Operating expenses for the three months ended September 30, 2024, were $21,640,000, up from $9,564,000 in the same period of 2023, indicating a 126% increase [25]. - Research and development expenses rose to $15,543,000 for the three months ended September 30, 2024, compared to $7,580,000 in the same period of 2023, marking a 105% increase [25]. Cash and Assets - The company ended Q3 2024 with $320.7 million in cash, cash equivalents, and short-term investments, down from $336.1 million as of June 30, 2024, primarily due to cash outflows from operating activities [15]. - Cash and cash equivalents decreased to $39,314,000 as of September 30, 2024, down from $70,169,000 on December 31, 2023 [24]. - Total current assets increased to $325,939,000 as of September 30, 2024, compared to $150,872,000 on December 31, 2023, reflecting a significant growth [24]. - The company expects its current cash reserves to fund operations through the end of 2026 [15]. Clinical Trials and Development - Ongoing clinical trials for RAP-219 include a Phase 2a trial in focal epilepsy, with topline data expected in mid-2025 [9]. - The FDA placed the IND for a Phase 2a trial of RAP-219 in diabetic peripheral neuropathic pain on clinical hold, requiring additional protocol information [10]. - The company is conducting a second multiple ascending dose trial (MAD-2) of RAP-219, with topline results expected in Q1 2025 [8]. - The company plans to initiate a Phase 2a trial in bipolar disorder patients with acute mania in 2025 [13]. Corporate Governance - The company has appointed new board members with extensive biotech experience to support its growth and innovation strategy [3]. Shareholder Equity and Liabilities - Total stockholders' equity improved to $323,114,000 as of September 30, 2024, compared to a deficit of $(25,634,000) on December 31, 2023 [24]. - Total liabilities decreased to $8,030,000 as of September 30, 2024, from $14,479,000 on December 31, 2023 [24]. - Weighted-average common shares outstanding increased to 34,855,907 for the three months ended September 30, 2024, from 1,529,216 in the prior year [25].

BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows: The Stifel Healthcare Conference in New York CityMonday, November 18, 2024, at 1:15pm ET The Jefferies London Healt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-42121 Rapport Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter ...

Financial Performance - The net loss for the second quarter of 2024 was $18.1 million, compared to $6.4 million for the same period last year[11]. - Total operating expenses for Q2 2024 were $20,800,000, a significant increase from $6,630,000 in Q2 2023, representing a 213% rise[22]. - Net loss for Q2 2024 was $18,121,000, up from a net loss of $6,411,000 in Q2 2023, indicating a 182% increase in losses[22]. - Net loss per share attributable to common stockholders improved to $(1.70) in Q2 2024 from $(4.45) in Q2 2023[22]. - Net cash used in operating activities was $(16,352,000) for Q2 2024, compared to $(6,599,000) in Q2 2023, reflecting a 148% increase in cash outflow[23]. - Net cash used in investing activities rose sharply to $(107,104,000) in Q2 2024, compared to $(86,000) in Q2 2023[23]. - Net cash provided by financing activities was $159,353,000 in Q2 2024, a significant turnaround from $(90,000) in Q2 2023[23]. - The net increase in cash, cash equivalents, and restricted cash for Q2 2024 was $35,897,000, compared to a decrease of $(6,775,000) in Q2 2023[23]. Research and Development - Research and development expenses increased to $15.7 million for the second quarter of 2024, up from $4.7 million in the prior year period[11]. - Research and development expenses surged to $15,689,000 in Q2 2024, compared to $4,721,000 in Q2 2023, marking a 232% increase[22]. - The company is on track to initiate a Phase 2a trial for RAP-219 in focal epilepsy in Q3 2024, with topline data expected in mid-2025[6]. - A Phase 2a trial for peripheral neuropathic pain is expected to begin in the second half of 2024[7]. - The company plans to initiate a Phase 2a trial in bipolar disorder patients in 2025[9]. - The company reported that RAP-219 was generally well tolerated in clinical trials, with no serious adverse events[5]. - The company expects results from a second multiple ascending dose trial (MAD-2) in the second half of 2024[5]. Capital and Assets - The company completed its initial public offering, raising $174.4 million in gross proceeds, which will fund the clinical development of its precision neuroscience pipeline[1]. - The company ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, expected to fund operations through the end of 2026[1]. - The total assets increased to $346.1 million as of June 30, 2024, compared to $155.4 million at the end of 2023[21].